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Mitochondrial cardiomyopathyMitochondrial (mt) DNA depletion and oxidative mtDNA damage have been implicated in the process of patholog-
ical cardiac remodeling. Whether these features are present in the early phase of maladaptive cardiac remodeling,
that is, during compensated cardiac hypertrophy, is still unknown.
We compared the morphologic and molecular features of mt biogenesis and markers of oxidative stress in human
heart from adult subjects with compensated hypertrophic cardiomyopathy and heart failure. We have shown that
mtDNA depletion is a constant feature of both conditions. A quantitative loss of mtDNA content was associated
with significant down-regulation of selected modulators of mt biogenesis and decreased expression of proteins in-
volved inmtDNAmaintenance. Interestingly,mtDNAdepletion characterized also the end-stage phase of cardiomy-
opathies due to a primary mtDNA defect. Oxidative stress damage was detected only in failing myocardium.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).HOS, oxidative phosphorylation;
hies; LCM, laser capturemicrodis-
enase; TEM, transmission electron
alphaPPARA;PGC-1α, peroxisome
RGC1A; NPPA, natriuretic peptide
eceptor alpha ESRRA; TFAM, mito-
ed) gamma;HPRT1, hypoxanthine
te–polyacrylamidegelelectropho-
ydrazine; DNP, antidinitrophenyl;
mide adenine dinucleotide phos-
.
erena Talarico per i Giovani nel
ocon Onlus. RWT is supported
e MRC Centre for Neuromuscu-
NHS Highly Specialised “Rare
39-064461484.
no).
. This is an open access article under1. Introduction
Heart failure (HF) is a complex chronic clinical syndrome and a leading
cause of morbidity andmortality in industrialized countries worldwide [1].
Central to thepathogenesis ofHF is left ventricular (LV) contractile dysfunc-
tion, due either to an ischemic insult (i.e., myocardial infarction), or to
nonischemic causes (e.g., hypertension, valvular heart diseases, genetic car-
diomyopathies, etc.). These insults induce an inexorable series of maladap-
tive phenomena that manifest clinically as changes in the size, shape, and
function of the heart, collectively referred to as pathological cardiac remodel-
ing. The initial event in pathologic remodeling is LV hypertrophy, which
eventually evolves to LV dilation and decreased contractility [2].
Clinical and experimental studies have shown that both impaired
oxidative phosphorylation (OXPHOS) and increased mitochondria-
derived oxidative stress are implicated in the pathophysiology of HF
[see for a Review 3,4]. Thus, the causes of mitochondrial dysfunction
in HF are the object of intense investigations, in view of possible thera-
peutic applications [5]. Previous studies have pointed to altered mito-
chondrial biogenesis as one of the causal mechanisms of OXPHOSthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(i.e., peroxisome proliferator-activated receptor alpha, PPARA aliases
PPARα; peroxisome proliferator-activated receptor gamma, coactivator
1 alpha, PPARGC1A aliases PGC-1α) involved in energymetabolismmod-
ulation and mitochondrial biogenesis has been shown in several exper-
imental models of HF [6–11]. However, recent works suggest that the
mechanisms at play aremore complex in human than in animalmodels.
For example, Karamanlidis et al. showed thatmitochondrial dysfunction
in the failing human heart is attributable to mitochondrial DNA
(mtDNA) depletion rather than decreased transcriptional activity of
the mitochondrial genome [12] and pointed to altered mtDNA replica-
tion and oxidative-dependent mtDNA damage as possible mechanisms.
In addition, an unresolved issue with potential therapeutic implications
is whether and to what extent the derangement in mitochondrial bio-
genesis observed in HF is present in the early phase of cardiac remodel-
ing, that is, during compensated hypertrophy.
In the present work, we aimed to evaluate mitochondrial biogenesis
and oxidative damage in compensated myocardial hypertrophy and HF
in the adult human heart. To this purpose, we compared ultrastructural,
biochemical, and molecular features of myocardial samples from pa-
tients with sarcomeric hypertrophic cardiomyopathy (HCM) (as a
model of compensated myocardial hypertrophy) and end-stage ische-
mic cardiomyopathy. For further comparison, we looked for changes
in mitochondrial biogenesis and oxidative stress in hypertrophic
nonfailing and failing hearts associated with a primary mtDNA defects
(all patients with mitochondrial tRNA mutations).
2. Materials and methods
2.1. Patients
All studies conformed to Sapienza, University of Rome Ethical Com-
mittee protocols. Hypertrophic, nonfailing, myocardial samples were
obtained from septal myectomy procedures performed on patients
with sarcomeric HCM with obstructive physiology (HCM group,
n=10). LV myocardial samples from patients with end-stage HF (HF
group, n=15) were obtained from transplant procedures. We selected
only failing hearts with proven ischemic etiology based both on clinical
records and grossmorphologic findings.We used as controls [nonfailing
heart (NHF) group] LV myocardial samples obtained either from donor
hearts, which were unsuitable for transplantation (n=5), or from au-
topsies of subjects who died for noncardiac causes (i.e., traffic accident),
obtained from the Forensic Pathology Service, Institute of Legal Medi-
cine of Seville, Spain (n=5, obtained within 4 h from death).
Inaddition,weanalyzedLVmyocardial samplesobtainedeitheratautopsy
(performed within 4 h from death, n=3) or cardiac transplant (n=3) from
patients with genetically provenmitochondrial cardiomyopathies (MICs).
2.2. Gross analysis, histology, and enzyme histochemistry
All explanted hearts were weighted and photographed. The epicar-
dial coronary arteries were examined, and the presence and degree of
luminal narrowing were evaluated. The myocardium was carefully
inspected with short axis sections. Myectomy samples from HCM pa-
tients were grossly inspected and measured after surgery.
For routine histological analysis, multiple samples from the left ventri-
cle, ventricular septum (VS), and coronary arterieswere embedded in par-
affin, and 5-micronmeter-thick sections were stained with hematoxylin–
eosin, periodic acid–Schiff and Masson trichrome stain.
Myocardial samples from left ventricle and myectomy were collected,
avoiding areas of scarring, and immediately snap-frozen in liquid
nitrogen-chilled isopentane, both in cryovials for molecular analyses and
in Optimal Cutting Temperature Compound embedding compound for en-
zymehistochemistry and laser capturemicrodissection (LCM) experiments.
To identify mitochondrial respiratory chain-deficient cardiomyocytes,
we performed sequential cytochrome c oxidase (COX) and succinatedehydrogenase (SDH) reactions on frozen sections from the left and
right ventricles. Combining the histo-enzymatic mitochondrial reactions
for COX (brown) and SDH (blue) normally results in a brown precipitate
within the cell in the presence of normal COX activity. As a consequence
of mtDNA depletion and/or multiple deletions, mitochondrial protein
synthesis is impaired, resulting in a significant reduction in COX activity.
In contrast, activity of the entirely nuclear-encoded SDH is retained.
Thus, cells with mtDNA defects are highlighted as blue, respiratory-
deficient cells following the sequential COX/SDH reaction.
2.3. Ultrastructural and morphometric analysis
Mitochondrial ultrastructure was studied in myocardial samples by
transmission electron microscopy (TEM). One-cubic millimeter myo-
cardial blocks were dissected from three hearts from each study group
and immediately fixed in 2.5% phosphate buffered glutaraldehyde. Tis-
sue dehydration and resin embedding and staining were performed as
described [13]. Grids were observed with a Zeiss EM 10 (ZEISS
Obercocken, Germany) (TEM), and 15 random fields at 8000×magnifi-
cation were acquired and stored as TIFF images (Digital Micrograph
3.4TM, Gatan GMBH, Munchen, Germany). Image analysis was per-
formed using ImageJ 64 1.48a (GNU License, National Institute of
Health, Bethesda MD, USA). Mitochondria were counted, the perimeter
of each organelle was manually traced, and the mitochondrial area was
automatically measured. Both the total and the mean cross-sectional
mitochondrial area were then obtained for each acquired field. The sar-
comere area was also manually measured for each image, and the ratio
between totalmitochondrial area and sarcomere areawas then derived.
2.4. Molecular analyses
Prior to each experiment, sections stained with hematoxylin and
eosin andMasson trichrome stainwere obtained fromeach frozenmyo-
cardial sample for morphological examination to exclude the presence
of extensive fibrosis.
Total DNA from LV myocardial tissue was extracted byWizard Geno-
mic DNA Purification Kit (Promega, Madison, WI, USA). Total RNA was
isolated from LV tissue using the SV total RNA isolation kit (Promega,
Madison, WI, USA). RNA amount was measured with NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Inc. Wilmington, DE,
USA), and total RNA was reverse-transcribed to cDNA using System Ca-
pacity cDNAReverse Transcription Kits (Applied Biosystems, Life technol-
ogies Italia, MB, Italy) according to manufactures guidelines.
2.5. Quantification of mtDNA and LCM analysis
Total DNAwas obtainedboth frommyocardial homogenates and from
myocytes microdissected by LCM (Leica LMD 7000, Leica Microsystem,
MI, Italy). For the latter, serial 5-μm-thick frozen sections were mounted
on a polyethylene foil slide and stained with hematoxylin and eosin. Sec-
tions were observed under light microscope with a 40× objective. Small
groups of myocytes (5–10 cells) were microdissected by a ultraviolet
laser and collected on an adhesive cap of nanotubes as previously de-
scribed [14]. Samples were digested with proteinase K (25μg/100μl)
over night at 37°C, preamplified by TaqMan® PreAmp Master Mix kit
(Life Technologies Italia, MB, Italy) according to manufactures guidelines.
Absolute quantification of mtDNA was performed by the standard curve
method as previously detailed [14]. The technique involves obtaining
the ratio of an unknown variable (number of copies of mtDNA) to a
known factor (number of copies of a nuclear DNA gene). With each
assay, a standard curve for mtDNA and nDNA was generated using serial
known dilutions of a vector in which the regions used as template for the
two amplifications were cloned tail to tail to have a ratio of 1:1 of the ref-
erencemolecules [15]. The absolutemtDNAcopynumber per cellwas ob-
tained by the ratio of mtDNA to nDNA values multiplied by two (as two
copies of the nuclear gene are present in a cell). Evaluation of mtDNA
Table 1
Characteristics of patients with compensated HCM and end-stage ischemic heart disease
NHF (n=10) HCM (n=10) HF (n=15)
Age in years, median (range) 43 (17–72) 45 (36–59) 57 (45–67)
Gender, male 7 7 14
EF (%) 58±7# 63±4⁎ 24.6±2⁎
Cardiac Index (L/min/m2) na 2.87±0.43 2.28±0.04⁎⁎
PWP, mm Hg na 13.5±3.34 22.2±2.7⁎⁎⁎
PAP, mm Hg na 24.8±3.85 33.4±3.3⁎⁎⁎
Treatments
ACEis na 0 15
β-blockers na 3 13
Statins na 0 3
Associated disease
Diabetes na 0 5
Dyslipidaemia na 0 5
Hypertension na 3 8
NHF= non failing heart; HCM= hypertrophic cardiomyopathy; HF= heart failure.
na: not available.
# : EF refers only to the five heart donors. EF values were not available for the autoptic
cases.
⁎ Pb .001 vs. NFH.
⁎⁎ Pb .01 vs. HCM.
⁎⁎⁎ Pb .001 vs. HCM.
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Polymerase Chain Reaction (PCR) as described [15] and expressed as
mtDNA/nuclear DNA ratio.
2.6. Gene expression analysis by quantitative real-time PCR
The relative expression of the following genes was evaluated by
quantitative Real Time PCR using TaqMan probe chemistry by means
of inventoried and custom6-carboxyfluorescein (FAM)-labeled TaqMan
MGB probe (Life Technologies Italia, MB, Italy) according to the
manufacturer's instructions (Supplemental Table 1): natriuretic peptide
A (NPPA), a molecular marker of cardiac hypertrophy; PPAR-α, a critical
regulator of cardiac oxidative metabolism; PGC1-α; nuclear respiratory
factor 1 (NRF1); estrogen-related receptor alpha (aliases ERRα), impor-
tant regulators of mitochondrial biogenesis; mitochondrial transcrip-
tion factor A (TFAM) and polymerase (DNA directed) gamma (POLG),
core components of the mitochondrial transcription; and replication
machinery. In all samples, the relative expression of each target gene
was evaluated with the comparative threshold cycle (ΔCt) method re-
spect to one control (reference sample) andnormalized to thehypoxan-
thine phosphoribosyltransferase 1 rRNA housekeeping gene.
2.7. Western blot analysis
Frozen myocardial tissue was homogenized with the Radio-
Immunoprecipitation Assay lysis buffer [50-mM Tris–HCl pH8, 150-mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1% sodium dodecyl sulphate
(SDS), 1-mM phenylmethylsulfonyl fluoride, 10-mg/ml aprotinin,
10-mg/ml leupeptin, and 10 mg/ml pepstatin] and centrifuged at
14000 g for 10 min at 4°C. The protein concentration was measured
by protein assay (Bio-rad Laboratories s.r.l, Hercules, CA, USA). Equal
amount of protein (40 μg) was separated by 12% sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) or precast
4–20% Bolt™ Mini Gels (Invitrogen ™, Life Technologies Italia, MB,
Italy) and transferred to a polyvinylidene fluoride (PVDF) membrane.
The following primary antibodies were used: antimouse monoclonal
PGC-1α (Calbiochem, Millipore, MA, USA); antirabbit monoclonal
ERRα (Abcam, Cambridge, UK); antirabbit polyclonal TFAM (ATLAS an-
tibodies AB, AlbaNova University Center, Stockholm, Sweden);
antimouse β-Actin (−Aldrich, St-Louis, MO, USA). Primary antibodies
were visualized using horseradish peroxidase-conjugated secondary
antibodies (Jackson ImmunoResearch, Laboratories, Inc., USA). Signals
were detected by enhanced chemiluminescence (Promega corporation,
Madison, WI, USA).
2.8. Oxyblot procedures
Total myocardial protein carbonylation was measured using the
OxyBlot Protein Oxidation Detection Kit (Chemicon, Millipore, MA, USA)
according to the manufacturer's protocol. Briefly, carbonyl groups were
derivatized by reaction with 2,4-dinitrophenylhydrazine for 15 min.
Dinitrophenyl (DNP)-derivatized proteins were resolved by 12% SDS-
PAGE and transferred to a PVDF membrane. Membranes were incubated
1 h at room temperature with anti-DNP primary antibodies (1:150) and
thenwith goat antirabbit IgG (horseradish peroxidase conjugated) antibod-
ies (1:300) for 1 h.
2.9. Antioxidant enzyme activities
Antioxidant enzymes activities were evaluated as previously report-
ed [16]. Briefly, for catalase (CAT) activity, 70 μg of tissue homogenates
was added to 100-mM phosphate buffer, pH 6.8, containing 10-mM
H2O2. CAT activity was determined following the decrease in absor-
bance at 240 nm of H2O2 for 30 s at 25°C [17]. The activity was calculat-
ed using an H2O2 extinction coefficient of 43.6×103 M−1×cm−1and
was expressed as μmol/min/mg of protein.For glutathione peroxidase (GPx) activity, 70 μg of tissue homogenate
was added to 100-mM phosphate buffer, pH 7.4, containing 0.5-mM EDTA,
1.0-mM NaN3, 0.25-mMNADPH, 2.25-mMGSH, and 1.0-U/ml glutathione
reductase. After addition of 0.24-mM tert-butil hydroperoxide (Sigma-
Aldrich, St-Louis, MO, USA), the change in optical density of Nicotinamide
adenine dinucleotide phosphate (NADPH) was monitored spectrophoto-
metrically at 340 nm for 2.0 min at 25°C [18]. GPx activity was calculated
using a molar extinction coefficient for NADPH of 6.22×103 M−1×cm−1
and expressed as nmol/min/mg protein.
Superoxide dismutase 2 (SOD2) activity was evaluated in 10 μg of
tissue homogenate using a Chemical Superoxide Dismutase Assay kit
(Cayman Chemical, Ann Arbor, MI, USA) as described [18]. Enzymatic
activity was expressed as units/mg of protein.
2.10. Lipid peroxidation
Oxidative stress level was evaluated by measuring malondialdehyde
(MDA) concentration, as a marker of lipid peroxidation. A Bioxytech
LPO-586 (Oxis International Inc. Prodotti Gianni, Milano, Italy) was used.
2.11. Statistical analysis
All data are expressed as mean±S.E.M. Data were analyzed by stan-
dard analysis of variance procedures followed by multiple pair-wise
comparisons adjusted with Bonferroni post-hoc test. Significance was
considered at Pb .05. Numerical estimates were obtained with the
Graphpad InStat 3 Version (Graphpad Inc. San Diego, CA, USA).
3. Results
3.1. Characterization of the study population
Characteristicsof thestudypopulationare reported inTable1.Briefly,pa-
tients with end-stage heart disease (HF group) were slightly older than pa-
tients with HCM and controls (mean age of HF group 57 years, vs. 45 and
43 years of age for the HCM and NHF patients, respectively). All HF patients
were either in New York Heart Association (NYHA) III or IV while patients
with HCM were either in NYHA I or II. The mean ejection fraction (EF) in
HF group was lower than 25% while it was within normal limits in HCM
andNHFgroups, as expected. Asmolecularmarkers ofmyocardial hypertro-
phy and HF, we evaluated the gene expression level of NPPA. As expected,
106 A. Pisano et al. / Cardiovascular Pathology 25 (2016) 103–112increased levels of NPPA were observed in ventricular samples obtained
from hypertrophic and failing hearts (Supplemental Fig. 1).3.2. Morphologic features
Gross and histologic evaluation confirmed the clinical diagnosis in all
explanted hearts from patients with ischemic cardiomyopathy: in 10 cases
(66%), there was severe atherosclerosis of the epicardial coronary arteries,
complicated by transmural myocardial infarction. In five hearts (33%),
there was diffuse intramural coronary artery disease, with multiple small
myocardial scars in the absence of significant stenosis of themajor epicardial
vessels. Surgical samples frommyectomy procedures in patients with HCM
showed marked myocytes hypertrophy and disarray, along with a mild in-
crease in interstitial collagen and focal microvascular disease, consistent
with the diagnosis of sarcomeric HCM. Control hearts were unremarkable,
both on gross and pathologic examination. Sequential COX/SDH reactions,
performed to identify respiratory chain-deficient cardiac myocytes in the
three groups, showed rare, scattered (b1 per high-power field) COX-Fig. 1. Combined COX-SDH histochemistry and mtDNA amount inmyocardium from compensa
reactions formitochondrial enzymes COX and SDH inNHFs, compensatedHCMs, and heart failu
(COX-SDH stain, original magnification ×20). (B) mtDNA amount measured in cardiac homog
ratio). Both NHF and HCM show a significant reduction of mtDNA amount as compared to N
and HF. Both HCM and HF show a reduction in MTCO1 level as compared to NHF. (D) mtDN
(n=6), and HF (n=7) (expressed as mtDNA copy per cardiac myocyte). A statistically signific
to NHF. (E) Representative image of myocardium before and after microdissection of single my
formed in triplicate. Data are expressed as mean±S.E.M. ⁎Pb .05; ⁎⁎Pb .01; ⁎⁎⁎Pb .001 for HCM andeficient cells in the left ventricleof allHFsamplesand in8/10HCMsamples.
COX-deficient cells were never observed in controls (Fig. 1A).3.3. Hypertrophic and failing heart shows partial mtDNA depletion
As a marker of mitochondrial biogenesis we first analyzed the mtDNA
amount of whole heart homogenates in the three groups. We showed a
~30% decrease of mtDNA content (expressed as mtDNA/nuclear ratio)
both in HCM (n=10) and HF (n=15) as compared with NHF (n=10).
This was paralleled by a decreased expression of the mitochondrial gene
MTCOI, coding for a subunit of complex IV of the respiratory chain
(Fig. 1B and C). Since cardiac homogenate is not only composed of
cardiomyocytes but also of other tissue components (i.e., fibrosis, vessels,
etc.) thatmaybedifferently represented in the three study groups,weper-
formed LCM on frozen cardiac sections to selectively measure the mtDNA
amount in cardiomyocytes. By this technique,we confirmed the significant
mtDNA reduction in HF (57% decrease as compared with controls) while
there was a less-pronounced reduction (19%) in HCM (Fig. 1D and E).ted hypertrophy and end-stage HF. (A) Representative images of combined histochemical
re (HF). Scattered COX-deficient cardiacmyocytes (blue) are observed in bothHCMandHF
enate of NHF (n=10), HCM (n=10), and HF (n=15) (expressed as mtDNA/nuclear DNA
HF. (C)MTCO1messenger RNA relative expression in cardiac homogenate of NHF, HCM,
A amount in cardiac myocytes microdissected by laser capture from NHF (n=8), HCM
ant reduction of mtDNA copies per cardiac myocyte is observed only in HF as compared
ocytes (hematoxylin and eosin stain, original magnification ×40). Experiments were per-
d HF versus NHF.
Fig. 2. Expression levels of genes and proteins involved inmitochondrial biogenesis. (A)Messenger RNA relative expression levels of PGC-1α, NRF1, EERα, and PPARα. A significant decrease
ofNRF1 and EERαwas found inHF (dark gray) as compared to NHF.NRF1 levelswere significantly decreased also inHCM(light gray) as compared toNHF. Experimentswere performed in
triplicate. (B)Messenger RNA relative expression levels of TFAM and POLG. Both genes showed a general reduction, both in HF and HCM as compared to NHF. However, the reductionwas
statistically significant for POLG in HF (dark gray) and TFAM in HCM (light gray). Experiments were performed in triplicate. (C) Expression of selected proteins involved in mitochondrial
biogenesis and mtDNAmaintenance: representative western blot and densitometry are shown. Normalization relative to β-actin (mean of three experiments) showed a generalized re-
duction of TFAM both inHCMandHF as compared toNHF. PGC-1α levelswere similar in the three study groups. Data are expressed asmean±S.E.M. and are normalized to the level of NHF
(indicated by the line). ⁎Pb .05; ⁎⁎Pb .01; for HCM and HF versus NHF.
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proteins involved in mtDNA replication
We then evaluated that the hypothesis that reduced mtDNA content in
hypertrophic and failing hearts could be related to reduced mitochondrial
biogenesis. Accordingly, we measured the relative expression levels of
genes involved in mitochondrial biogenesis. As shown in Fig. 2A, PGC-1α,
the master regulator of mitochondrial biogenesis, was unchanged both inFig. 3.Mitochondrial density and morphology and CS activity. (A) Representative ultrastructura
dria per area (100 μm2) inmyocardium of NHF (n=3), HCM (n=3), and HF (n=3). Number ofm
summarizing the average mitochondrial size in myocardium of NHF, HCM, and HF. The mean c
pared to NHF. (D) CS activity in cardiac homogenate fromNHF, HCM, and HF. Cytrate synthase a
for HCM and HF versus NHF.HCM and HF, while selected transcriptional regulators that PGC-1α co-
activates behaved differently. In fact, both NRF1 and ERRα appeared reduced
in both conditions (up to25%decrease),while PPARα levelswereunchanged.
Finally, reductionof both TFAM, the key regulator ofmtDNA transcription and
mitochondrial POLG, was observed both in HCM and HF (Fig. 2B).
Western blot analysis confirmed a clear reduction of TFAM protein in
both HCM andHF groupswhile PGC-1αwas unchanged. However, pos-
sibly because of the small data set and the intrinsic interindividuall images of NHF, HCM, and HF samples. (B) Graph summarizing the number of mitochon-
itochondria is significantly increased both inHCMandHF as compared to NHF. (C) Graph
ross sectional area of mitochondria is significantly decreased both in HCM and HF as com-
ctivity was comparable in the three groups. Data are expressed asmean±S.E.M. ⁎⁎⁎Pb .001
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statistic significance (Fig. 2C).3.5. Cardiomyocytes from hypertrophic and failing heart show increased
number and reduced size of mitochondria
We performed ultrastructural morphometric analysis on a subset of
myocardial samples (NHF=3; HCM=3; HF=3) to evaluate both densi-
ty andmorphology ofmitochondria. Amean of 1251 isolatedmitochon-
dria (defined as organelles enclosed by a double contoured membrane)
were analyzed from each sample (range, 940–1690; standard deviation
±326.16). As shown in Fig. 3A, mitochondria in HCM and HF were in-
creased in number and appeared smaller as compared with controls.
These features weremore marked in HCM. In fact, the absolute number
of mitochondria per area was increased by 96% in HCM and 35% in HF
(Fig. 3B)while themean cross-sectional area of individualmitochondria
was reduced by 70% in HCM and 39% in HF, as compared with controls
(Fig. 3C). To assess if the observed mitochondrial remodeling in cardiac
hypertrophy and failure reflected changes in the total mitochondrial
volume mass, we evaluated the activity of citrate synthase (CS), a key
enzyme in the Krebs cycle. As shown in Fig. 3D, the activity of CS was
unchanged both in HCM and HF.3.6. Markers of oxidative stress and antioxidant enzyme activities are
increased only in end-stage failing hearts
Since myocardial oxidative damage has been implicated both in
mtDNA damage and in the progression to HF, we looked for
markers of oxidative stress in HCM and HF. Both MDA, a terminal
product of lipid peroxidation, and protein carbonylation, assessed
by oxyblot, were significantly increased only in HF (Fig. 4A and B).
We then evaluated the activities of the antioxidant enzymes CAT,
GPx, and SOD2. Only failing hearts showed a significant increase
of antioxidant enzymes, consistent with increased oxidative stress
in this condition (Fig. 4C).Fig. 4.Markers of oxidative stress and antioxidant enzymes activity. (A)MDA levels evaluated o
HF. (B) Representative western blot analysis and quantification by densitometry of total carbon
plemental Fig. 2A. Carbonylated proteins are increased inHF as compared to NHF. (C) Activities o
nmol/min/mg of protein), and SOD2 (expressed as U/mg of protein). Only failing hearts showed
parable in the three groups. Data are expressed as mean±S.E.M. ⁎⁎⁎Pb .001 for HF versus NHF.3.7. MICs show mtDNA depletion in the end-stage phase.
Genetic and biochemical data of patients with MIC are reported in
Table 2. Briefly, Patients 1–4 belong to unrelated families and harbored
heteroplasmic levels of the pathogenic m.3243ANGmutation in the mi-
tochondrial gene MTTL1 coding for tRNALeu. The clinical phenotype
ranged from encephalomyopathy with lactic acidosis (MELAS =
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like epi-
sodes) to myopathy and sensorineural deafness. HCM was diagnosed
in the course of cardiologic screening. Patient 5 belong to a large family
with isolated MIC caused by the homoplasmic m.4300ANG mutation in
the mitochondrial gene MTTI coding for tRNAIle (see 21 for a detailed
clinical history). Patient 6 [19] showed HCM and progressive hearing
impairment. He harbored homoplasmic levels of the pathogenic
m.4277CNTmutation in themitochondrial MTTI gene. Based on electro-
cardiographic and echocardiographic features (Table 3), patients were
divided into two groups, MIC with compensated cardiac hypertrophy
(hypertrophic [H] MIC, n=3) and end-stage MIC (HF MIC, n=3).
Consistent with the mitochondrial etiology, combined COX/SDH re-
actions on frozen heart sections showed a mosaic pattern of COX-
positive and COX-deficient cells, with a prevalence of the latter in the
presence of mutation levels above 90% (Fig. 5A). The more interesting
result, at molecular analysis, was the significant mtDNA reduction in
HF MIC as compared with both H MIC and controls. This feature was
paralleled by a relative down-regulation of TFAM and POLG genes as
compared to H MIC. Protein levels were unchanged (Fig. 5B–D).
A marked increase in oxidative stress was observed only in end-
stage MIC (Fig. 5E).
4. Discussion
Despite significant progress in cardiovascular medicine, HF remains
a leading cause of morbidity and mortality in industrialized countries.
Failing hearts invariably show abnormal energy metabolism, increased
reactive oxygen species (ROS) production and mitochondrial respirato-
ry chain dysfunction [20,21]. These are associated with impaired mito-
chondrial biogenesis, suggesting that mitochondria-targeted therapiesnwhole homogenate of NHF, HCM, and HF.MDA levelswere significantly increased only in
ylated protein fromNHF, HCM, and HF. The Ponceau S stainedmembrane is shown in sup-
f the antioxidant enzymes CAT (expressed as μmol/min/mg of protein), GPx (expressed as
a significant increase of CAT and GPx activity as compared toNHF. SOD2 activity was com-
Table 2
Genetic and biochemical features of MICs
Patient Phenotype mtDNA mutation % of mutation on heart
homogenate
Combined COX/SDH NPPA (mean±S.E.M.)
1 MELAS, diabetes m.3243 ANG
MTTL1
77% Scattered COX-negative fibers 4.96±1.18
2 MELAS m.3243 ANG
MTTL1
92% Prevalence of COX-negative fibers 5.6±0.22
3 MELAS m.3243 ANG
MTTL1
76% na na
4 Cardiomyopathy,
myopathy, CPEO, deafness
m.3243 ANG
MTTL1
89% Prevalence of COX-negative fibers na
5 (Patient IV-09 in
Taylor et al. 2003)
Isolated MIC m. 4300 ANG
MTTI
Homoplasmic Prevalence of COX-negative fibers 62.18±0.54
6 (Perli et al. 2012) Isolated MIC m.4277 CNT
MTTI
Homoplasmic Prevalence of COX-negative fibers 28.12±0.8
MELA: Smitochondrial encephalomyopathy, lactic acidosis, stroke-like episode.
na: not available.
CPEO: chronic progressive external opthalmoplegia.
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er impaired mitochondrial function and biogenesis are present already
in the early stage ofmyocardial remodeling, that is, during compensated
hypertrophy, and which is the underlying pathogenic mechanism.
Studies on animal models show that deregulation of mitochondrial
biogenesis is an early event in HF, and appears to be triggered by
down-regulation of the PGC-1α pathway [6,7,9,10]. However, results
obtained in animal models have not been verified in human, due to
the difficulties in obtaining surgical cardiac tissue samples frompatients
with compensated hypertrophy. In a previous study, Karamanlidis et al.
[23] analyzedmitochondrial biogenesis inmyocardial samples from hy-
pertrophic and failing right ventricles of pediatric patients undergoing
surgery for congenital heart disease. According to their results, both
the hypertrophic and failing ventricles showed a lower mtDNA content
as compared to normal hearts, suggesting that mitochondrial dysfunc-
tion is involved in both processes of compensated hypertrophy and
overt HF. However, the age difference between subjects with HF (medi-
an age: 0.8 months), compensated hypertrophy (median age: 6.3
years), and controls (median age: 12 years) could by itself account forTable 3
Clinical features of MIC patients
Gender AD Cause of death Electrocardiogram
Rhythm LVH Strain
H MIC
1 M 35 SD Sinus Yes Yes
2 M 45 SD Sinus Yes Yes
3 M 36 SD Sinus LBBB Yes No
FH MIC
4 M 30 CHF2 Sinus, biventricular PM No No
5 M 233 CHF Sinus Yes Yes
6 M 203 CHF Sinus Yes Yes
AD: age at death.
LVH: left ventricle hypertrophy.
LVEDD: left ventricular end-diastolic diameter.
LVESD: left ventricular end-systolic diameter.
LVWT: left ventricular wall thickness.
PW: posterior wall.
SD: sudden death.
RVH: right ventricle hypertrophy.
BB: beta blockers.
ACEis: ACE inhibitors.
LBBB: left bundle brank block.
PR: PR interval.
CHF: congestive heart failure.
PM: pace maker.
TWI: T-wave inversion.
N: normal.
1 Upper limit of normal.
2 Sudden death while waiting for cardiac transplant.
3 Cardiac transplant.some of the observed changes and made results difficult to interpret
[24]. The reported higher amount of mtDNA in control subjects, as com-
pared with patients with compensated hypertrophy and HF, could rea-
sonably be due, at least in part, to the induction of mitochondrial
biogenesis during heart growth [25,26].
In the present study, we focused our analysis on adult subjects. We
compared mitochondrial biogenesis and markers of oxidative stress in
myocardial samples from patients with either sarcomeric HCM (as a
model of compensated myocardial hypertrophy) or end-stage ischemic
cardiomyopathy, with age-matched controls. We showed that mtDNA
depletion and decreased levels of proteins involved in mtDNA mainte-
nance are common features to both conditions, suggesting that im-
paired mitochondrial biogenesis is an early event in cardiac
hypertrophic remodeling. mtDNA depletion in HCM was more evident
in the total heart homogenate as compared with dissected cardiac
myocytes. A likely explanation for this observation is that the mtDNA
content in total heart homogenate derives both from cardiac myocytes
and interstitial cells (i.e., fibroblast, endothelial, and smooth muscle
cells). In fact, interstitial tissue is invariably increased in HCM [27,28].Echocardiogram Medication
Other EF% LVEDD LVESD LVWT VS LVWT PW
RVH N N N 16 15 BB, ACEi
No 45 N N N1 N1 ACEi
Short PR 55 44.5 34.5 12.5 9.5 BB, ACEi
No 15 62 59 N1 N1 Dobutamine
TWI 17 82 72 25 16 BB, ACEi
TWI 25 69 63 21 18 BB, ACEi
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ed to have lower mtDNA amount as compared to cardiac myocytes
[29,30]. Thus, the total mtDNA amount in HCM homogenates may be
“diluted” by the interstitial cells.
Changes in mtDNA levels were paralleled by down-regulation of the
key modulators of mitochondrial biogenesis NRF1, ERRα, TFAM, and
POLG1 but not of PGC-1α, as previously reported in HF [12,31].
Both in compensated hypertrophy and in HF, the decrease inmtDNA
content is paralleled by an increase in the number of intermyofibrillar
mitochondria that appear smaller than controls, while the total mito-
chondrial mass is unchanged. The significance of these features is un-
clear and should be confirmed in a higher number of samples. Chen
et al. [32] recently showed that the increased number of small mito-
chondria in heart disease is caused by an altered mitochondrial fusion/
fission balance and speculated that this may be related to increased
myocyte apoptosis, contributing to HF.
Since reactive oxygen species have been implicated as potential
modulators of mitochondrial biogenesis [12], we then looked for
markers of oxidative damage inmyocardial samples from compensated
hypertrophy andHF. Lipid peroxidation and protein carbonylationwere
raised exclusively in the failing myocardium and were associated with
activation of the antioxidant enzymes CAT and GPx, while the activity
of themitochondrial antioxidant enzyme SOD2was unchanged, accord-
ing to previous observations [33,18].
All together our results show that impaired mitochondrial biogene-
sis is a constant feature of cardiac maladaptive remodeling being pres-
ent both in compensated HCM and in overt cardiac failure. Conversely,
oxidative stress damage is detected only in failing myocardium. Thus,
oxidative stress damage seems not to be a causative factor of impaired
mitochondrial biogenesis and mtDNA depletion in cardiac myocytes,
at least in this setting.
We then analyzed mitochondrial biogenesis and oxidative stress in
cardiomyopathies caused by mutations in genes coding for mt-tRNAs.
These mutations cause structural alteration and reduced stability of
mt-tRNAs that affect whole mitochondrial protein synthesis, leading
to a respiratory chain dysfunction. The net effect is the reduction in cel-
lular energetic proficiency and the increase in mitochondrial-derived
ROS production. A common feature of mitochondrial disease caused
by mtDNA mutations is the up-regulation of mitochondrial biogenesis,
to overcome the decrease in ATP levels due to respiratory chain dys-
function [34,35]. Accordingly, we observed induction of mitochondrial
biogenesis in the hypertrophic phase of MIC. However, failing MIC
showed mtDNA depletion and decrease of genes involved in mtDNA
maintenance. Again, marked oxidative stress damage was evident only
in the end-stage hearts.5. Conclusion
In conclusion, altered mitochondrial biogenesis, mtDNA depletion,
and oxidative stress damage are constant features of HF irrespective of
the underlying etiology. The mechanisms involved in deranged mito-
chondrial biogenesis and mtDNA depletion and the impact of this de-
rangement on the progression of pathological cardiac remodeling still
needs to be elucidated. Our results suggest that oxidative stress is not
implicated in mediating mtDNA depletion, at least in the early phase
of cardiac remodeling.Fig. 5.Markers of mitochondrial function and biogenesis and levels of carbonylated proteins i
enzymes COX and SDH in NHFs, MIC with compensated cardiac hypertrophy (H MIC), and e
both inHMIC andHFMIC. (B)mtDNA amount (mean±S.E.M.) inNHF (n=8), HMIC (n=3), an
myocytes (right). mtDNA depletion was observed in end-stage MIC, while a slight nonsig
(C) Messenger RNA relative expression levels of PGC-1α, NRF1, ERRα, TFAM, and POLG in NHF
increased in H MIC (light gray) as compared to NHF and HF MIC (dark gray). ±S.E.M. and are n
involved inmitochondrial biogenesis andmtDNAmaintenance: representative western blot an
malized to the level of NFH (indicated by the line). (E) Representative western blot analysis and
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